Low Fecal Calprotectin Predicts Sustained Clinical Remission in Inflammatory Bowel Disease Patients: A Plea for Deep Remission

Mooiweer, Erik; Severs, Mirjam; Schipper, Marguérite E.I.; Fidder, Herma H.; Siersema, Peter D.; Laheij, R.J.F.; Oldenburg, Bas

doi:10.1093/ecco-jcc/jju003

Cited by 104 publications

(64 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Measurement of faecal calprotectin might have enhanced the study. However, retrospective analysis of mucosal calprotectin in this cohort was not associated with outcomes,59 and another group has been unable to correlate faecal calprotectin and histological activity, even if a low calprotectin was associated with a better clinical outcome 60…”

Section: Discussionmentioning

confidence: 57%

Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up

Bryant

Burger

Delo

et al. 2015

Gut

369

281

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 57%

Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up

Bryant

Burger

Delo

et al. 2015

Gut

369

281

View full text Add to dashboard Cite

show abstract

“…As summarized in Figure 1, in current practice, the dosage of the fecal calprotectin has two primary interests: -To differentiate organic from functional intestinal diseases, both in adult and children; -To monitor IBD therapy and predict relapses [74,75].…”

Section: Discussionmentioning

confidence: 99%

Fecal calprotectin in inflammatory bowel diseases: update and perspectives

Manceau

Chicha-Cattoir²,

Puy

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBDs) are chronic diseases that result from the inflammation of the intestinal wall, suspected in any patient presenting with intestinal symptoms. Until recently, the diagnosis was mainly based on both clinical and endoscopic arguments. The use of an easy, fast, reliable, non-invasive, and inexpensive biological assay is mandatory not only in diagnosis but also in evolutionary and therapeutic monitoring. To date, the fecal calprotectin is the most documented in this perspective. This marker allows the discrimination between functional and organic bowel processes with good performance. The determination of the fecal calprotectin level contributes to the evaluation of the degree of disease activity and to monitoring of therapeutic response.

show abstract

“…35 In light of this, absolute FC values may be less predictive than ΔFC that is, change in FC levels. Deep remission with neither symptoms nor active inflammation is strongly associated with normal FC,32 while active inflammation in a symptomatic individual is equally associated with very elevated FC levels. A moderately elevated FC level may be seen in patients with resolving inflammation (going into remission) or in patients heading for a flare or in patients who have ongoing elevated levels of inflammation.…”

Section: Can Fc Predict Relapse In Ibd?mentioning

confidence: 95%

Can faecal calprotectin predict relapse in inflammatory bowel disease: a mini review

Chew

Mansfield

2016

Frontline Gastroenterol

View full text Add to dashboard Cite

Crohn's disease and ulcerative colitis are chronic inflammatory disorders affecting the gastrointestinal tract. Faecal calprotectin is a protein complex of the S-100 family of calcium-binding proteins present in inflammatory cells that can be measured in stool samples, which act as a biomarker for bowel inflammation. Elevated faecal calprotectin has been shown to reflect the presence of ongoing mucosal inflammation, which improves with mucosal healing. The aim of this review was to evaluate the available evidence on the ability of faecal calprotectin to predict a relapse in inflammatory bowel disease. Multiple retrospective studies have shown that patients who relapse have significantly higher levels of calprotectin in their stool compared with non-relapsers, especially in ulcerative colitis. Elevated faecal calprotectin postoperatively in Crohn's disease was also shown to be indicative of a relapse. However, the association of a raised faecal calprotectin and relapse is not universal and may be explained by the different patterns of mucosal inflammatory activity that exist. In conclusion, we put forward our hypothesis that changes such as a rise in faecal calprotectin levels may be more predictive of a relapse than absolute values.

show abstract

Low Fecal Calprotectin Predicts Sustained Clinical Remission in Inflammatory Bowel Disease Patients: A Plea for Deep Remission

Abstract: Low calprotectin levels identify IBD patients who remain in stable remission during follow-up.

Cited by 104 publications

References 31 publications

Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up

Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up

Fecal calprotectin in inflammatory bowel diseases: update and perspectives

Can faecal calprotectin predict relapse in inflammatory bowel disease: a mini review

Contact Info

Product

Resources

About